Clinical Trials Browser

Phase 1 × Completed × nilotinib × Clear all

Neoplasms

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Phase 1 Completed

23 enrolled

Sarcoma

Chordoma

NCT07138378 2025-08-22

XS003-11

Phase 1 Completed

128 enrolled

Tumor-Agnostic

Neoplasms

NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Phase 1 Completed

11 enrolled 9 charts

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1 Completed

326 enrolled 2 FDA

MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01702064 2021-01-05

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Phase 1 Completed

11 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01077544 2020-12-29

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Phase 1 Completed

15 enrolled 20 charts 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01223898 2020-12-09

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Phase 1 Completed

19 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01456676 2020-12-09

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Phase 1 Completed

11 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00135005 2020-12-08

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Phase 1 Completed

59 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01155817 2020-04-15

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Phase 1 Completed

33 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT02253277 2019-05-01

CoRNea

Phase 1 Completed

5 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01220648 2015-05-05

NICOLI

Phase 1 Completed

4 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase 1 Completed

14 enrolled

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Clinical Trials

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Nilotinib With Radiation for High Risk Chordoma

XS003-11

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

CoRNea

NICOLI

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib